These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 38948747)
1. ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for Dick JK; Hicks D; Krishna VD; Sangala JA; Zandstra BT; Baehr C; Verbeek JS; Cragg MS; Cheeran MC; Pravetoni M; Hart GT bioRxiv; 2024 Jun; ():. PubMed ID: 38948747 [TBL] [Abstract][Full Text] [Related]
2. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants. Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040 [TBL] [Abstract][Full Text] [Related]
3. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection. Lu M; Yao W; Li Y; Ma D; Zhang Z; Wang H; Tang X; Wang Y; Li C; Cheng D; Lin H; Yin Y; Zhao J; Zhong G Microbiol Spectr; 2023 Aug; 11(4):e0110023. PubMed ID: 37395664 [TBL] [Abstract][Full Text] [Related]
4. ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks. Alfaleh MA; Alsulaiman RM; Almahboub SA; Nezamuldeen L; Zawawi A; Aljehani ND; Yasir M; Abdulal RH; Alkhaldi R; Helal A; Alamri SS; Malki J; Alhabbab RY; Abujamel TS; Alhakamy NA; Alnami A; Algaissi A; Hassanain M; Hashem AM Antib Ther; 2024 Jan; 7(1):53-66. PubMed ID: 38371953 [TBL] [Abstract][Full Text] [Related]
5. Protective Efficacy of Novel Engineered Human ACE2-Fc Fusion Protein Against Pan-SARS-CoV-2 Infection In Vitro and in Vivo. Yu B; Drelich A; Hsu J; Tat V; Peng BH; Wei Q; Wang J; Wang H; Wages J; Mendelsohn AR; Larrick JW; Tseng CT J Med Chem; 2023 Dec; 66(24):16646-16657. PubMed ID: 38100534 [TBL] [Abstract][Full Text] [Related]
6. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides. Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663 [TBL] [Abstract][Full Text] [Related]
11. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2. Wines BD; Kurtovic L; Trist HM; Esparon S; Lopez E; Chappin K; Chan LJ; Mordant FL; Lee WS; Gherardin NA; Patel SK; Hartley GE; Pymm P; Cooney JP; Beeson JG; Godfrey DI; Burrell LM; van Zelm MC; Wheatley AK; Chung AW; Tham WH; Subbarao K; Kent SJ; Hogarth PM Front Immunol; 2022; 13():889372. PubMed ID: 35967361 [TBL] [Abstract][Full Text] [Related]
12. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo. Havranek B; Lindsey GW; Higuchi Y; Itoh Y; Suzuki T; Okamoto T; Hoshino A; Procko E; Islam SM Commun Biol; 2023 May; 6(1):513. PubMed ID: 37173421 [TBL] [Abstract][Full Text] [Related]
13. Targeting SARS-CoV-2 infection through CAR-T-like bispecific T cell engagers incorporating ACE2. Dogan M; Kozhaya L; Placek L; Karabacak F; Yigit M; Unutmaz D Clin Transl Immunology; 2022; 11(10):e1421. PubMed ID: 36285327 [TBL] [Abstract][Full Text] [Related]
14. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity. Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q Front Immunol; 2022; 13():1041860. PubMed ID: 36532082 [TBL] [Abstract][Full Text] [Related]
15. Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo. Zhang Z; Zeng E; Zhang L; Wang W; Jin Y; Sun J; Huang S; Yin W; Dai J; Zhuang Z; Chen Z; Sun J; Zhu A; Li F; Cao W; Li X; Shi Y; Gan M; Zhang S; Wei P; Huang J; Zhong N; Zhong G; Zhao J; Wang Y; Shao W; Zhao J Cell Discov; 2021 Aug; 7(1):65. PubMed ID: 34385423 [TBL] [Abstract][Full Text] [Related]
16. Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2. Verstraete MM; Heinkel F; Li J; Cao S; Tran A; Halverson EC; Gene R; Stangle E; Silva-Moreno B; Arrafi S; Bavananthasivam J; Fung M; Eji-Lasisi M; Masterman S; Xanthoudakis S; Dixit S; Babcook J; Clavette B; Fogg M; Escobar-Cabrera E MAbs; 2023; 15(1):2212415. PubMed ID: 37229608 [TBL] [Abstract][Full Text] [Related]
17. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses. Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993 [TBL] [Abstract][Full Text] [Related]
18. David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors. Alfaleh MA; Zawawi A; Al-Amri SS; Hashem AM MAbs; 2022; 14(1):2057832. PubMed ID: 35380919 [TBL] [Abstract][Full Text] [Related]